08:56 AM EDT, 07/14/2025 (MT Newswires) -- Biodexa Pharmaceuticals ( BDRX ) said Monday it has filed a clinical trial application with the European Medicines Agency for trial of Serenta in patients with familial adenomatous polyposis.

Familial adenomatous polyposis is a genetic disease that if untreated often leads to colorectal cancer.

The application is required to obtain approval to begin a clinical trial in Europe, the company said.

The application follows US Food & Drug Administration fast track and European orphan drug designations, the company said.

Shares of the company were up more than 3% in recent premarket activity.